header

About admin

This author has not yet filled in any details.
So far admin has created 68 blog entries.

Potential Risk of Exposure to Toxic Compounds When Using Certain Hemodialysis Machines Manufactured by Fresenius Medical Care

May 9th, 2022|

The U.S. Food and Drug Administration (FDA) is evaluating the potential risk of exposure to non-dioxin-like (NDL) polychlorinated biphenyl acids (PCBAs) and NDL polychlorinated biphenyls (PCBs) with the following hemodialysis machines manufactured by Fresenius Medical Care: the 2008T, 2008K2, and 2008K models. The 2008K2 and 2008K models are no longer manufactured but may still be

Nephrology Roundtable Discussion

March 25th, 2022|

Please join Qsource ESRD Networks for a Nephrology Roundtable discussion as we work through current barriers and ways that we can improve the kidney disease experience for ESRD patients. Join in the discussion led by our panel of Nephrologists who serve on our Network Boards and Community Coalitions. Date: Friday, April 15th Time: 12pm CST

Baxter Class 1 Recall

March 18th, 2022|

Baxter Healthcare is recalling SIGMA Spectrum Infusion Pumps with Master Drug Library (Version 8) and Spectrum IQ Infusion Systems with Dose IQ Safety Software (Version 9) due to the risk of not alarming for repeated upstream occlusion events. After an upstream occlusion alarm, failure to fully resolve any upstream occlusion before restarting the infusion can

Sodium Acetate Injection-USP by Fresenius Kabi

March 5th, 2022|

Fresenius Kabi USA is voluntarily recalling seven lots of Sodium Acetate Injection, USP, 400 mEq/100 mL (4 mEq/mL), 100 mL fill in a 100 mL vial to the user level due to the presence of particulate matter found in reserve and/or stability sample vials. Microscopic and elemental analyses determined the presence of particulates composed of

Do Not Use E25Bio COVID-19 Tests: FDA Safety Communication

February 9th, 2022|

The U.S. Food and Drug Administration (FDA) is warning people not to use the E25Bio COVID-19 Direct Antigen Rapid Test. This test has not been authorized, cleared, or approved by the FDA for distribution or use in the United States, and it may include false labeling representing that the test is authorized by the FDA.

Vaccination Webinar Speaker

January 28th, 2022|

Marie Philipneri, MD, PhD Dr. Marie Philipneri is a Professor of Medicine at Saint Louis University School of Medicine. She joined the Division of Nephrology at Saint Louis University (SLU) in 2000. After earning a medical degree from University of Guyana (1994), she completed residency in internal medicine at University of Missouri Kansas City and

COVID-19 Facility-Specific Data Feedback and Technical Assistance Report

December 8th, 2021|

This four-page report reviews the facility’s COVID-19 data as a way to ensure the accuracy and completeness of the weekly NHSN submissions – highlighting areas that may need attention and providing guidance on resolving those issues (pages 1 and 2). It summarizes the patient and staff vaccination rates to drive improvement toward the CMS goal (page

Dr. John Kevin Tucker

November 19th, 2021|

Dr. John Kevin Tucker is Vice-President for Education at Mass General Brigham and Assistant Professor of Medicine at Harvard Medical School. He is also co-director of Harvard Medical School’s Master in Clinical Service Operations program. His clinical appointment is at Brigham and Women’s Hospital, where he focuses on the management of chronic kidney disease patients,

Lidocaine HCl Topical Solution 4% Due to Super Potency

October 14th, 2021|

Buena, NJ, Teligent Pharma, Inc. is voluntarily recalling five lots of Lidocaine HCl Topical Solution 4% because the firm's testing has found it to be super potent based on an Out of Specification (OOS) result obtained at the 18-month stability timepoint. Use of the super potent product would result in a higher than intended lidocaine